SCHEMBL6026972

SCHEMBL6026972

CCCN(CCO)CCCOc1cc2ncnc(Nc3cn(CC(=O)Nc4cccc(F)c4)nn3)c2cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 15/20 0.73
AURKB Q96GD4 9/20 0.73
PDGFRB P09619 3/20 0.61
FLT4 P35916 3/20 0.61
FLT3 P36888 2/20 0.61
EGFR P00533 3/20 0.52
KDR P35968 2/20 0.52
CSK P41240 2/20 0.52
PLK4 O00444 1/20 0.52
CIT O14578 1/20 0.52
MUSK O15146 1/20 0.52
EPHB6 O15197 1/20 0.52
MAP3K7 O43318 1/20 0.52
RIPK2 O43353 1/20 0.52
STK10 O94804 1/20 0.52
MAP4K4 O95819 1/20 0.52
CHEK2 O96017 1/20 0.52
ABL1 P00519 1/20 0.52
ERBB2 P04626 1/20 0.52
LCK P06239 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5039179 0.90 AURKA (0.74) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL2049092 0.89 FLT4 (0.78) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL6027595 0.89 AURKA (0.71) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL6027344 0.88 PDGFRB (0.69) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL2052845 0.87 FLT4 (0.82) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL6090156 0.85 AURKA (0.71) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL2051707 0.85 FLT4 (0.78) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL2051886 0.85 FLT4 (0.77) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL4288439 0.84 AURKA (1.00) AURKAAURKBPDGFRBFLT4FLT3
SCHEMBL2053597 0.83 FLT4 (0.74) AURKAAURKBPDGFRBFLT4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US claimed
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors ASTRAZENECA AB (SE) 2006-08-10 US disclosed
EP-1644361-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS Astrazeneca AB (SE) 2006-04-12 EP disclosed
WO-2004113324-A1 CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS ASTRAZENECA AB (SE) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178382-A1 Chinazoline derivatives as aurora kinase inhibitors AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885PDGFRB 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.